Novartis (NYSE:NVS)

Shell sign at dusk

J.P. Morgan’s 5 Top International Stock Picks

While the U.S. markets have absolutely been on fire, the terminally slow-growth European bourses have been miserable this year for the most part, lagging domestic markets by 22% in U.S. ...
Read Full Story »
Volkswagen Golf 2015

Companies Spending the Most on R&D

For the third consecutive year, the company spending the most on research and development (R&D) was Germany’s Volkswagen. The automaker’s 2014 R&D spending will total $13.5 billion, just ahead of ...
Read Full Story »
biotech

Makers of the 10 Top-Selling Cancer Drugs Catch the Eye of Analyst

One sad thing for almost every citizen in the United States is that at one point almost all of us will either have cancer or have a friend or relative ...
Read Full Story »
DNA

Upcoming Catalysts Could Drive Seven Biotech and Health Care Stocks Higher

Binary events are often the key element in moving a biotech or health care stock higher. Negative binary results or actions often can move shares drastically lower. We scan our ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: BioMarin, Family Dollar, Lululemon, SunTrust and More

It is Monday and 24/7 Wall St. has seen many new analyst research calls that have to be covered. The bull market is on, with stocks having hit new highs on Friday, but ...
Read Full Story »
down market

Why You Buy Big Pharma If the Market Crashes

Defensive sectors have done well this year, with utilities leading the way. One of the reasons is that despite the market hitting new all-time highs, there remains a wall of ...
Read Full Story »
Monkey evil

Top Analyst Upgrades and Downgrades: Avanir, Avon, Broadcom, Endo, Oracle, Wynn and More

Earnings season is in full swing and investors want to make money in upside while avoiding the downside. 24/7 Wall St. reviews dozens of analyst research reports each morning for ...
Read Full Story »
Pills

Akebia, MediWound Post Gains Following IPOs

Mediwound Ltd. (NASDAQ: MDWD) is an Israel-based biopharma firm that is developing, manufacturing and commercializing novel products to address severe burns and other hard-to-heal wounds and connective tissue disorders. The ...
Read Full Story »
biotech

Biotech Buyout Bolsters Novartis Cancer Portfolio

Pharmaceutical giant Novartis A.G. (NYSE: NVS) announced Monday morning that it will acquire startup biotech CoStim Pharmaceuticals. Terms of the deal were not revealed, but it will bolster Novartis's cancer ...
Read Full Story »
Pills

Novartis Announces Share Buybacks and Business Expansion

Speculation has run hot that Swiss drugmaker Novartis A.G. (NYSE: NVS) would announced further restructuring at its investor day in London. Instead, on Friday the company announced a $5 billion ...
Read Full Story »
Pills

Shire, Novartis Deals: Pharmaceutical Shakeups Continue

The wave of mergers and acquisitions in health care continues with two big announcements Monday. Drug maker Shire PLC (NASDAQ: SHPG) will acquire the rare disease biopharmaceutical company ViroPharma (NASDAQ: ...
Read Full Story »
biotech

Wall Street Sees Big Biotech Making Tens of Billions in Two Critical Areas

Investors make big money in biotechnology stocks when they focus on areas that cut across a wide swath of the population. From obesity to food allergies to prostate cancer, the ...
Read Full Story »
global economy

UBS Offers Eight Well-Known International Large Cap Dividend Ruler Stocks

With yields on 10-year Treasury bonds up nearly 1.5% since early May and briefly touching 3.0% last week, the impact of higher rates on stocks continues to be top of ...
Read Full Story »
pills

Drugmakers Pfizer, Bayer, Novartis May Join Bidding for Onyx

Although Amgen Inc.’s (NASDAQ: AMGN) $10 billion offer for Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) was unsolicited and not exactly a stalking horse bid, that’s what many observers expect to be ...
Read Full Story »
Pills

Jefferies Raises Price Targets on Pharmaceutical Stocks to Buy

As the pharmaceuticals industry looks toward restructuring and separation of undervalued assets, Jefferies analysts have prepared a highly proprietary sum of the parts analysis for their coverage universe to find ...
Read Full Story »